Sequencing and Genomic Technologies (SGT) is a basic science research core affiliated with the Duke Cancer Institute (DCI) that offers a full range of state-of-the-art genomic services. For answers to common questions, please visit our Frequently Asked Questions and Policies.
Director Devi Swain Lenz is available for project consultations.
Same Great mRNA-seq, New Low Price
The Sequencing and Genomic Technologies core facility s happy to announce lower pricing for mRNA-seq for all sample sizes, starting at $181/sample. Contact us today for a consultation!
News & Announcements
Swain Lenz to Speak at Large Genomic Conference
Sequencing and Genomic Technologies Director, Devjanee (Devi) Swain Lenz, will be one of the invited panel speakers at the Festival of Genomics and Biodata conference in Boston on October 4-5.
The Festival is the world’s largest open access genomics event and covers a host of topics. There will be 120 sessions with 150 invited speakers and 100 exhibitors. Swain Lenz will be on a panel discussing “The Resolution Revolution: Going Beyond Single-Cell Analysis As You Know It.”
New Year, New NextSeq
The Sequencing and Genomic Technologies core facility has acquired a new sequencing platform. The llumina NextSeq 1000 produces 100-400 M reads at a variety of read lengths, including 300 bp paired-end reads at a fraction of the price of the NextSeq 500 and MiSeq.
Inside the Massive Genome Sequencing Operation Guiding Duke's COVID Response
How a group of genome sequencing research scientists at Duke steered the university's COVID-19 response.
Oxford Nanopore Technology GridION: Putting More Bases in Their Places
The Sequencing and Genomic Technologies (SGT) Core Facility recently added an Oxford Nanopore GridION long-read sequencer to its arsenal. The GridION provides cost-effective, ultra-long sequencing reads of hundreds of kilobases to help answer research questions that short read sequencers cannot.